The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by about 50% via APRIL inhibition.
Jackson Peter Kim, MD
Advertisement
Jackson Peter Kim, MD, clinical assistant professor in the Division of Nephrology at Stanford Health Care
Articles by Jackson Peter Kim, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
2
Fifth Death Confirmed in NYC Legionnaires' Outbreak
3
Small Workflow Changes Close Big Gaps in CKM Screening
4
Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%
5